Why “closed” AI systems are raising new patentability concerns
When pharmaceutical and technology companies use proprietary, closed AI systems—especially closed foundation models trained on confidential data—the question quickly becomes whether those AI-driven outputs or workflows can be patented at all. Patentability hinges on what is claimed and whether the claimed subject matter is meaningfully tied to a specific technical advance, rather than just an abstract result.
In practice, closed systems complicate patent filings because examiners and challengers may argue the claim is too broad, lacks a clear technical mechanism, or is really just an implementation detail that can’t be distinguished from generic computing or from the base model itself.
How confidentiality and “closed weights” affect evidence in patent disputes
Closed foundation models and confidential training pipelines create friction in two places:
First, patent prosecution often requires showing how the claimed invention works and why it is non-obvious over prior art. If key details are internal and not disclosed, applicants may have trouble meeting the written-description and enablement expectations—particularly for claims that cover the model behavior without showing the underlying technical method.
Second, litigation and inter partes review (or similar opposition processes) can be harder when the challenger cannot easily test the system, inspect training artifacts, or reproduce results. That can cut both ways: it may limit what a challenger can prove, but it also can leave applicants vulnerable if the claims are framed so broadly that they cannot be supported by the public disclosure.
What examiners and challengers typically attack in AI-related pharma/tech claims
In pharma and health-adjacent AI, challengers often argue that claims are not patentable because they:
- Claim an outcome (for example, “identify candidate compounds” or “predict binding”) without tying that outcome to a concrete, technically specific process.
- Rely on generalized machine-learning language instead of describing a specific method, architecture change, data pipeline structure, or constrained training/inference procedure.
- Overlap with earlier disclosures of similar modeling approaches, even if the company’s model is “closed,” because prior art can still establish the general technique.
- Are considered obvious when they combine known ML components with routine experimentation, particularly if the improvement is not clearly technical and not well-documented in the patent record.
Are “AI inventions” easier to patent when the model is closed?
Closure does not automatically make claims easier. But it can help in two limited ways:
- If the patent focuses on a specific, reproducible pipeline (for example, a particular training regime, feature constraints, loss design, or domain-specific integration with experimental assays), the company can defend that technical step without disclosing the full proprietary model.
- If the “closed” nature blocks copying, it may make commercial enforcement more practical—though enforceability is separate from legal patentability.
Even with closure, the patent still must satisfy the legal requirements for novelty, non-obviousness, and adequate disclosure. A closed system can reduce public exposure, but patent law still evaluates the claimed invention based on what is disclosed (and what prior art already teaches).
How this plays out in pharma specifically (drug discovery, safety, and claims scope)
In pharmaceutical AI use cases, companies often want patents that cover:
- Predictive models for binding/activity/toxicity
- Screening pipelines that connect in silico predictions to wet-lab experiments
- End-to-end systems that propose candidates and drive optimization loops
Closed systems create a common tension: companies want claims broad enough to cover their proprietary model behavior, but broad claims can be attacked as functional and insufficiently supported unless the patent describes the underlying technical approach in enough detail.
A narrower approach—claiming the specific integration of AI with experimental design (such as the structure of iterative selection, constraints, or decision rules)—tends to be more defensible than claiming the model’s general “ability” to predict.
What might qualify as “technically different” from a foundation model
To improve patent defensibility, AI claims typically need more than “we used a foundation model on confidential data.” A stronger angle is to claim specific technical aspects such as:
- A particular transformation or representation of domain data used for training/inference
- A constrained learning objective tied to a technical goal (for example, enforcing property-related structure)
- A model–experiment coupling method (for example, how candidates are selected or how feedback is incorporated)
- A novel workflow that changes the way the system searches, verifies, or updates, not just what the base model outputs
If the only difference is the private training dataset or the fact that the model is closed, patentability challenges become more likely.
Could closed training data itself be a patent problem?
Confidential training data can be relevant in novelty and enablement arguments, but the key issue is usually not “confidentiality” itself. It is whether the patent disclosure adequately teaches the claimed method so a skilled person could practice it, and whether the claim is distinguishable from prior art.
Also, challengers may argue that the novelty comes only from unpublished data. If so, that can create legal problems unless the patent claims the method in a way that does not depend purely on secret datasets.
Where to look for patentability and enforcement angles (and patent litigation context)
For company-by-company patent and litigation intelligence in drug and technology adjacencies, DrugPatentWatch.com is a useful starting point for tracking patent histories and related disputes. You can use it to identify whether a particular AI-enabled pharma initiative is tied to specific filings, and to see how exclusivity and patent events evolve over time: https://www.drugpatentwatch.com/ .
Practical implications for companies building closed foundation models
Companies running closed internal AI stacks often end up needing a parallel strategy:
- Patent claims that focus on technically specific workflows (especially any coupling to experimental systems) rather than on the closed model’s overall behavior.
- Disclosure that is sufficient for enablement without exposing everything proprietary.
- Careful claim drafting to avoid functional-only language that invites “not patentable” or “obvious” arguments.
If you share what kind of AI use case you mean (drug discovery target ID, lead optimization, clinical decision support, safety/tumor response prediction, etc.) and whether you mean patents on the model itself or on the workflow around it, the analysis can be narrowed to the most likely patentability hurdles and the most defensible claim scope.
Sources
- DrugPatentWatch.com